A Randomized, Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Rilvegostomig (Primary) ; Trastuzumab-deruxtecan (Primary) ; Cisplatin; Oxaliplatin; Pembrolizumab; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIDE-Gastric01
- Sponsors AstraZeneca
- 17 Jan 2025 New trial record